1. Home
  2. GKOS vs CHSCN Comparison

GKOS vs CHSCN Comparison

Compare GKOS & CHSCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • CHSCN
  • Stock Information
  • Founded
  • GKOS 1998
  • CHSCN N/A
  • Country
  • GKOS United States
  • CHSCN United States
  • Employees
  • GKOS 995
  • CHSCN N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • CHSCN Farming/Seeds/Milling
  • Sector
  • GKOS Health Care
  • CHSCN Industrials
  • Exchange
  • GKOS Nasdaq
  • CHSCN Nasdaq
  • Market Cap
  • GKOS 5.1B
  • CHSCN N/A
  • IPO Year
  • GKOS 2015
  • CHSCN N/A
  • Fundamental
  • Price
  • GKOS $90.26
  • CHSCN $24.95
  • Analyst Decision
  • GKOS Strong Buy
  • CHSCN
  • Analyst Count
  • GKOS 13
  • CHSCN 0
  • Target Price
  • GKOS $155.00
  • CHSCN N/A
  • AVG Volume (30 Days)
  • GKOS 1.0M
  • CHSCN N/A
  • Earning Date
  • GKOS 04-30-2025
  • CHSCN N/A
  • Dividend Yield
  • GKOS N/A
  • CHSCN N/A
  • EPS Growth
  • GKOS N/A
  • CHSCN N/A
  • EPS
  • GKOS N/A
  • CHSCN N/A
  • Revenue
  • GKOS $383,481,000.00
  • CHSCN N/A
  • Revenue This Year
  • GKOS $27.84
  • CHSCN N/A
  • Revenue Next Year
  • GKOS $27.99
  • CHSCN N/A
  • P/E Ratio
  • GKOS N/A
  • CHSCN N/A
  • Revenue Growth
  • GKOS 21.85
  • CHSCN N/A
  • 52 Week Low
  • GKOS $77.91
  • CHSCN N/A
  • 52 Week High
  • GKOS $163.71
  • CHSCN N/A
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 41.57
  • CHSCN 47.05
  • Support Level
  • GKOS $86.16
  • CHSCN $24.87
  • Resistance Level
  • GKOS $94.55
  • CHSCN $25.01
  • Average True Range (ATR)
  • GKOS 6.54
  • CHSCN 0.26
  • MACD
  • GKOS 1.11
  • CHSCN 0.02
  • Stochastic Oscillator
  • GKOS 54.51
  • CHSCN 63.51

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About CHSCN CHS Inc Preferred Class B Series 2 Reset Rate

CHS Inc is an integrated agricultural enterprise, that provides grain, food, and energy resources to businesses and consumers. Its Energy segment produces and provides wholesale distribution of petroleum products and transportation of those products. Its Ag segment, which is the key revenue driver, purchases and processes or resells grains and oilseeds; serves as a wholesaler and retailer of crop inputs; produces and markets ethanol. Its Nitrogen Production segment consists of equity method investment in CF Nitrogen, which entitles the purchase of up to a specified quantity of granular urea and UAN annually from CF Nitrogen. Geographically, the company derives maximum revenue from North America and the rest from South America, Asia Pacific, Europe, Middle East, and Africa (EMEA).

Share on Social Networks: